Shots:

• Under the amended agreement- the offer price increased from $44.5 to $49/QIAGEN share in cash- representing a premium of 35% to the closing price of QIAGEN's ordinary shares on the Frankfurt Prime Standard on Mar 2- 2020- making the latest deal value as $12.5B
• The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of outstanding QIAGEN shares at the end acceptance period on Aug 10- 2020- with $95M reimbursement to Thermo Fisher- if the minimum acceptance threshold is not met
• QIAGEN’s Supervisory and Managing Boards reaffirm unanimous recommendation that all shareholders accept and tender all their QIAGEN shares in the offer prior to the end of the acceptance period. The transaction is expected to be completed in H1’21

  Ref: PRNewswire | Image: MPO

Related News: Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B